Cardiff Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 31
- Market Cap
- -
- Introduction
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
- Conditions
- CRCMetastatic Colorectal CancerKRAS/NRAS Mutation
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 113
- Registration Number
- NCT06106308
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸St. Bernards Medical Center, Jonesboro, Arkansas, United States
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
- Conditions
- Metastatic Colorectal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 23
- Registration Number
- NCT05593328
- Locations
- 🇺🇸
Mayo Clinic in Arizona - Phoenix Campus, Phoenix, Arizona, United States
🇺🇸Central Arkansas Radiation Therapy Institute - Cancer Center, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 43
- Registration Number
- NCT04752696
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Kansas Medical Center, Westwood, Kansas, United States
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal CancerKRAS Gene Mutation
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cardiff Oncology
- Registration Number
- NCT04446793
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
- Conditions
- Metastatic Colorectal CancerKRAS Gene Mutation
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 68
- Registration Number
- NCT03829410
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Prev
- 1
- 2
- Next
News
Pancreatic Cancer Pipeline Expands with 80+ Companies Advancing Novel Therapies
DelveInsight's 2025 report reveals over 80 companies are actively developing more than 80 pipeline therapies for pancreatic ductal adenocarcinoma treatment.
Cardiff Oncology Secures Second Patent for Onvansertib in Bevacizumab-Naïve mCRC Patients
Cardiff Oncology has been granted a new patent (No. 12,263,173) covering the combination treatment of onvansertib with bevacizumab for all bevacizumab-naïve metastatic colorectal cancer patients through 2043.
Pipeline Analysis Reveals 85+ Drugs in Development for Metastatic Prostate Cancer Treatment
DelveInsight's comprehensive analysis identifies over 80 pharmaceutical companies actively developing 85+ pipeline drugs for metastatic prostate cancer treatment.
Cardiff Oncology's Onvansertib Shows Promise in Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology reports positive Phase 2 data for onvansertib in combination with Zytiga and prednisone for metastatic castration-resistant prostate cancer (mCRPC).
Cardiff Oncology's Onvansertib Shows Promising Results in RAS-Mutated Metastatic Colorectal Cancer Trial
Cardiff Oncology's onvansertib, combined with standard-of-care, demonstrated a 64% objective response rate (ORR) in first-line RAS-mutated metastatic colorectal cancer (mCRC) patients.
KRAS Inhibitors Market Set for Growth with Novel Therapies Targeting Key Mutations in Cancer
• The KRAS inhibitors market is projected to grow significantly, driven by increasing cancer incidence and advancements in targeted therapies. • KRAZATI (adagrasib) is expected to lead in revenue among approved KRAS inhibitors, surpassing LUMAKRAS (sotorasib) during the forecast period. • Pan-KRAS drugs, targeting multiple KRAS mutations, hold substantial market potential due to their broader applicability across cancer types. • Emerging therapies like JDQ443 and avutometinib are poised to transform the treatment landscape, offering new options for patients with KRAS-mutated cancers.
Cardiff Oncology's Onvansertib Enters Phase 2 Trial for KRAS/NRAS-Mutated Metastatic Colorectal Cancer
Cardiff Oncology has initiated a Phase 2 randomized trial (ONSEMBLE) of onvansertib in patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).